SUVENPHAR — Suven Pharmaceuticals Balance Sheet
0.000.00%
- IN₹292.42bn
- IN₹286.58bn
- IN₹10.51bn
Annual balance sheet for Suven Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 444 | 1,898 | 5,279 | 4,859 | 8,234 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,567 | 1,574 | 2,930 | 1,849 | 2,008 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 3,916 | 5,648 | 11,279 | 10,110 | 12,632 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4,557 | 5,349 | 5,620 | 7,662 | 7,868 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 11,728 | 14,745 | 18,296 | 19,657 | 22,541 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2,004 | 2,197 | 2,103 | 1,588 | 1,069 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 3,280 | 2,937 | 3,024 | 2,306 | 2,034 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 8,448 | 11,808 | 15,272 | 17,352 | 20,507 |
Total Liabilities & Shareholders' Equity | 11,728 | 14,745 | 18,296 | 19,657 | 22,541 |
Total Common Shares Outstanding |